nach oben

Erschienen in:

01.03.2007 | Original Paper

Drug Use and Medication Adherence among HIV-1 Infected Individuals

verfasst von: Charles H. Hinkin, Terry R. Barclay, Steven A. Castellon, Andrew J. Levine, Ramani S. Durvasula, Sarah D. Marion, Hector F. Myers, Douglas Longshore

Erschienen in: AIDS and Behavior | Ausgabe 2/2007

Einloggen, um Zugang zu erhalten

Abstract

This longitudinal study examined the impact of drug use and abuse on medication adherence among 150 HIV-infected individuals, 102 who tested urinalysis positive for recent illicit drug use. Medication adherence was tracked over a 6-month period using an electronic monitoring device (MEMS caps). Over the 6-month study drug-positive participants demonstrated significantly worse medication adherence than did drug-negative participants (63 vs. 79%, respectively). Logistic regression revealed that drug use was associated with over a fourfold greater risk of adherence failure. Stimulant users were at greatest risk for poor adherence. Based upon within-participants analyses comparing 3-day adherence rates when actively using versus not using drugs, this appears to be more a function of state rather than trait. These data suggest that it is the acute effects of intoxication, rather than stable features that may be characteristic of the drug-using populace, which leads to difficulties with medication adherence.

Arnsten, J. H., Demas, P. A., Farzadegan, H., Grant, R. W., Gourevitch, M. N., Change, C. J., et al. (2001). Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: Comparison of self-report and electronic monitoring. Clinical Infectious Diseases, 33(18), 1417–1423.PubMedCrossRef

Arnsten, J., Demas, P., Grant, R., Gourevitch, M., Farzadegan, H., Howard, A. A., et al. (2002). Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. Journal of General Internal Medicine, 17(5), 377–381.PubMed

Berg, K. M., Demas, P. A., Howard, A. A., Schoenbaum, E. E., Gourevitch, M. N., & Arnsten, J. H. (2004). Gender differences in factors associated with adherence to antiretroviral therapy. Journal of General Internal Medicine, 19(11), 1111–1117.PubMedCrossRef

Bangsberg, D. R., Bronstone, A., & Hofmann, R. (2002). A computer based assessment detects regimen misunderstandings and nonadherence for patients on HIV antiretroviral therapy. AIDS Care, 14(1), 3–15.PubMedCrossRef

Bangsberg, D. R., Hecht, F. M., Charlebois, E. D., Zolopa, A. R., Holodniy, M., Sheiner, L., et al. (2000). Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS, 14(4), 357–366.PubMedCrossRef

Burke, L. E. (2001). Electronic measurement. In Burke L. E., & Ockene I. S. (Eds.), Compliance in healthcare and research. Armonk, NY: Futura Publishing Company.

Burney, K. D., Krishnan, K., Ruffin, M. T., Zhang, D., & Brenner, D. E. (1996). Adherence to single daily dose of aspirin in a chemoprevention trial. An evaluation of self-report and microelectronic monitoring. Archives of Family Medicine, 5, 297–300.PubMedCrossRef

Chang, L., Ernst, T., Speck, O., Patel, H., DeSilva, M., Leonido-Yee, M., et al. (2002). Perfusion MRI and computerized cognitive test abnormalities in abstinent methamphetamine users.PsychiatryResearch: Neuroimaging, 114(2), 65–79.CrossRef

Chesney, M., Morin, M., & Sherr, L. (2000). Adherence to HIV combination therapy. Social Science & Medicine, 50, 1599–1605.CrossRef

Chermack, S. T., Roll, J., Reilly, M., Davis, L., Kilaru, U., & Grabowski, J. (2000). Comparison of patient self-reports and urinalysis results obtained under naturalistic methadone treatment conditions. Drug & Alcohol Dependence, 59(1), 43–49.CrossRef

Colfax, G., & Shoptaw, S. (2005). The methamphetamine epidemic: Implications for HIV prevention and treatment. Current HIV/AIDS Reports, 2(4), 194–199.PubMedCrossRef

Crisp, B. R., Williams, M., Timpson, S., & Ross, M. W. (2004). Medication compliance and satisfaction with treatment for HIV disease in a sample of African-American crack cocaine smokers. AIDS and Behavior, 8(2), 199–206.PubMedCrossRef

DiMatteo, M. R., Lepper, H. S., & Croghan, T. W. (2000). Depression is a risk factor for noncompliance with medical treatment: Meta-analysis of the effects of anxiety and depression on patient adherence. Archives of Internal Medicine, 160(14), 2101–2107.PubMedCrossRef

Ehrman, R. N., Robbins, S. J., & Cornish, J. W. (1997). Comparing self-reported cocaine use with repeated urine tests in outpatient cocaine abusers. Experimental and Clinical Psychopharmacology, 5(2), 150–156.PubMedCrossRef

Fendrich, M., Johnson, T. P., Wislar, J. S., Hubbell, A., & Spiehler, V. (2004). The utility of drug testing in epidemiological research: Results from a general population survey. Addiction, 99, 197–208.PubMedCrossRef

Garber, M. C., Nau, D. P., Erickson, S. R., Aikens, J. E., & Lawrence, J. B. (2004). The concordance of self-report with other measures of medication adherence: A summary of the literature. Medical Care, 42(7), 649–652.PubMedCrossRef

Garcia de Olalla, P., Knobel, H., Carmona, A., Gnelar, A., Lopez-Colmes, J. L., & Cayla, J. A. (2002). Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. Journal of Acquired Immune Deficiency Syndrome, 30, 105–110.CrossRef

Gifford, A. L., Bormann, J. E., Shively, M. J., Wright, B. C., Richman, D. D., & Bozzette, S. A. (2000). Predictors of self-reported adherence and plasma HIV concentrations in patient on multidrug antiretroviral regimens. Journal of Acquired Immune Deficiency Syndrome, 23, 386–395.

Golin, C.E., Liu, H., Hays, H.D., Miller, L.G., Beck, C.K., Ickovics, J., et al. (2002). A prospective study of predictors of adherence to combination antiretroviral medication. Journal of General Internal Medicine, 17, 756–765.PubMedCrossRef

Gonzalez, R., Rippeth, J. D., Carey, C. L., Heaton, R. K., Moore, D. J., Schweinsburg, B.C., et al. (2004). Neurocognitive performance of methamphetamine users discordant for history of marijuana exposure. Drug and Alcohol Dependence, 76(2), 181–190.PubMedCrossRef

Halkitis, P.N., Kutnick, A.H., & Slater, S. (2005). The social realities of adherence to protease inhibitor regimens: Substance use, health care and psychological states. Journal of Health Psychology, 10(4), 545–558.PubMedCrossRef

Hinkin, C. H., Castellon, S. A., Atkinson, J. H., & Goodkin, K. (2001). Neuropsychiatric aspects of HIV infection among older adults. Journal of Clinical Epidemiology, 54(Suppl 1), S44–52.PubMedCrossRef

Hinkin, C. H., Castellon, S. A., Durvasula, R. S., Hardy, D. J., Lam, M. N., Mason, K. I., et al. (2002). Medication adherence among HIV+ adults: Effects of cognitive dysfunction and regimen complexity. Neurology, 59, 1944–1950.PubMed

Hinkin, C. H., Hardy, D. J., Mason, K. I., Castellon, S. A., Durvasula, R. S., Lam, M. N., et al. (2004). Medication adherence in HIV-infected adults: Effect of patient age, cognitive status, and substance abuse. AIDS, 18(1), S19–S25.PubMedCrossRef

Hogg, R. S., Heath, K. V., Yip, B., Craib, K. J., O’Shaughnessy, M. V., Schechter, M. T., et al. (1998). Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. Journal of the American Medical Association, 279(6), 450–454.PubMedCrossRef

Howard, A. A., Arnsten, J. H., Lo, Y., Vlahov, D., Rich, J. D., Schuman, P., et al. (2002). A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS, 16, 2175–2182.PubMedCrossRef

Ingersoll, K. (2004). The impact of psychiatric symptoms, drug use, and medication regimen on non-adherence to HIV treatment. AIDS Care, 16(2), 199–211.PubMedCrossRef

Kalichman, S. C., Ramachandran, B., & Catz, S. (1999). Adherence to combination antiretroviral therapies in HIV patients of low health literacy. Journal of General Internal Medicine, 14, 267–273.PubMedCrossRef

Kilpatrick, B., Howlett, M., Sedgwick, P., & Ghodse, A. H. (2000). Drug use, self report and urinalysis. Drug and Alcohol Dependence, 58, 111–116.PubMedCrossRef

Kimmerling, M., Wagner, G., & Ghosh-Dastidar, B. (2003). Factors associated with accurate self-reported adherence to HIV antiretrovirals. International Journal of STD & AIDS, 14, 281–284. .CrossRef

Letendre, S. L., Cherner, M., Ellis, R. J., Marquie-Beck, J., Gragg, B., Marcotte, T., et al. (2005). The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: Biological correlates of disease. AIDS, 19(Suppl 3), S72–S78.PubMedCrossRef

Levine, A., Hardy, D., Miller, E., Castellon, S., Longshore, D., & Hinkin, C. (2006). The effect of recent stimulant use on sustained attention in HIV-infected adults. Journal of Clinical and Experimental Neuropsychology, 28, 29–42.PubMedCrossRef

Levine, A., Hinkin, C, Marion, S., Keuning, A., Castellon, S., Lam, M., et al. (In press, 2006). Adherence to antiretroviral medications in HIV: Differences in data collected via self-report and electronic monitoring. Health Psychology..

Liu, H., Golin, C. E., Miller, L. G., Hays, R. D., Beck, C. K., Sanandaji, S., et al. (2001). A comparison study of multiple measures of adherence to HIV protease inhibitors. Annals of Internal Medicine, 134, 968–977.PubMed

Lu, N. T., Taylor, B. G., & Riley, K. J. (2001). The validity of adult arrestee self-reports of crack cocaine use. American Journal of Drug & Alcohol Abuse, 27(3), 399–419.CrossRef

Matthews, W.C., Mar-Tang, M., Ballard, C., Colwell, B., Abulhosn, K., Noonan, C., et al. (2002). Prevalence, predictors, and outcomes of early adherence after starting or changing antiretroviral therapy. AIDS Patient Care and STDs, 16(4), 157–172.CrossRef

Mohammed, H., Kieltyka, L., Richardson-Alston, G., Magnus, M., Fawal, H., Vermund, S. H., et al. (2004). Adherence to HAART among HIV-infected persons in Rural Louisiana. AIDS Patient Care and STDs, 18(5), 289–296.PubMedCrossRef

Murphy, E. L., Collier, A. C., Kalish, L. A., Assmann, S. F., Para, M. R., Flanigan, T. P., et al. (2001). Highly active antiretroviral therapy decreases mortality and morbidity in patient with advanced HIV disease. Annals of Internal Medicine, 135, 17–26.PubMed

Nieuwkerk, P. Y., Sprangers, M. A., Burger, D. M., Hoetelmans, R. M., Hugen, P. W., Danner, S. A., et al. (2001). Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort. Archives of Internal Medicine, 161, 1962–1968.PubMedCrossRef

O’Brien, M. K., Petrie, K., & Raeburn, J. (1992). Adherence to medication regimens: Updating a complex medical issue. Medical Care Review, 49, 435–454.PubMedCrossRef

Ory, M. G., & Mack, K. A. (1998). Middle-aged and older people with AIDS. Research on Aging, 20, 653–664.

Palella, F. J. Jr., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., et al. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. New England Journal of Medicine, 338(13), 853–860.PubMedCrossRef

Paterson, D. L., Swindells, S., Mohr, J., Brester, M., Vergis, E. N., Squier, C., et al. (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine, 133, 21–30.PubMed

Paterson, D., Potoski, B., & Capitano, B. (2002). Measurement of adherence to antiretroviral medications. JAIDS, 31, S103–S106.PubMed

Rabkin, J. G., & Chesney, M. (1999). Treatment adherence to HIV medications: The Achilles heel of the new therapeutics. In Ostrow D., Kalichman S. (Eds.), Behavioral and mental health impacts of new HIV therapies. New York: Plenum Press.

Reback, C. J., Larkins, S., & Shoptaw, S. (2003). Methamphetamine abuse as a barrier to HIV medication adherence among gay and bisexual men. AIDS Care, 15(6), 775–785.PubMedCrossRef

Rippeth, J. D., Heaton, R. K., Carey, C. L., Marcotte, T. D., Moore, D. J., Gonzalez, R., et al. (2004). Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. Journal of the International Neuropsychological Society, 10(1), 1–14.PubMedCrossRef

Sharpe, T.T., Lee, L.M., Nakashima, A.K., Elam-Evans, L.D., & Fleming, P.L. (2004). Crack cocaine use and adherence to antiretroviral treatment among HIV-infected black women. Journal of Community Health, 29(2), 117–27.PubMedCrossRef

Simoni, J. M., Frick, P. A., & Huang, B. (2006). A longitudinal evaluation of a social support model of medication adherence among HIV-positive men and women on antiretroviral therapy. Health Psychology, 25(1), 74–81.PubMedCrossRef

Smith, M. Y., Rapkin, B. D., Morrison, A., & Kammerman, S. (1997). Zidovudine adherence in persons with AIDS: Relation of patient beliefs about medications to self-termination of therapy. Journal of General Internal Medicine, 12, 216–223.PubMed

Spitzer, R. L., Williams, J. B., Gibbon, M., & First, M., B. (1992). The Structured Clinical Interview for DSM-III--R (SCID): I. History, rationale, and description. Archives of General Psychiatry, 49(8), 624–629.PubMed

Stein, M. D., Rich, J. D., Maksad, J., Chen, M. H., Hu, P., Sobota, M., et al. (2000). Adherence to antiretroviral therapy among HIV-infected methadone patients: Effect of ongoing illicit drug use. American Journal of Drug and Alcohol Abuse, 26(2), 195–205.PubMedCrossRef

Stephenson, B. J., Rowe, B. H., Haynes, R. B., Macharia, W. M., & Leon, G. (1993). Is this patient taking the treatment as prescribed? Journal of the American Medical Association, 269, 2779–2781.PubMedCrossRef

Tassiopoulos, K. B., Bernstein, J., Heeren, T., Levenson, S., Hingson, R., & Bernstein, E. (2004). Hair testing and self report of cocaine use by heroin users. Addiction, 99(5), 590–597.PubMedCrossRef

Tucker, J. S., Orlando, M., Burnam, M. A., Sherbourne, C. D., Kung, F., & Gifford, A. L. (2004). Psychosocial mediators of antiretroviral nonadherence in HIV-positive adults with substance use and mental health problems. Health Psychology, 23(4), 363–370.PubMedCrossRef

Volkow, N. D., Chang, L., Wang, G., Fowler, J. S., Leonido-Yee, M., Franceschi, D., et al. (2001). Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. American Journal of Psychiatry, 158(3), 377–382.PubMedCrossRef

Wainberg, M. A., & Friedland, G. (1998). Public health implications of antiretroviral therapy and HIV drug resistance. Journal of the American Medical Association, 279, 1977–1983.PubMedCrossRef

Wohl, D., Stephenson, B., Golin, C., Kiziah, N., Rosen, D., Ngo, B., et al. (2003). Adherence to directly observed antiretroviral therapy among human immunodeficiency virus-infected prison inmates. Clinical Infectious Diseases, 36, 1572–1576.PubMedCrossRef

Titel: Drug Use and Medication Adherence among HIV-1 Infected Individuals
verfasst von: Charles H. Hinkin
Terry R. Barclay
Steven A. Castellon
Andrew J. Levine
Ramani S. Durvasula
Sarah D. Marion
Hector F. Myers
Douglas Longshore
Publikationsdatum: 01.03.2007
Verlag: Springer US
Erschienen in: AIDS and Behavior / Ausgabe 2/2007
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI: https://doi.org/10.1007/s10461-006-9152-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2007

Prevalence of HIV, Hepatitis B, Syphilis, and Chlamydia Among Adults Seeking Treatment for a Mental Disorder in Southern India

Alcohol Consumption, Art Usage and High-Risk Sex Among Women Infected with HIV

Sero-positive African Americans’ Beliefs about Alcohol and Their Impact on Anti-retroviral Adherence

Human Immunodeficiency Virus (HIV) and Substance Use Risk Behaviors among Tri-ethnic Adolescents of Florida

Awareness and Attitudes Regarding Microbicides and Nonoxynol-9 use in a Probability Sample of Gay Men